Growth Capitalist (https://growthcapitalist.com/tag/biomed/page/18/)
AspenBio Pharma (APPY) has raised $3.1 million in a CMPO/Overnight transaction. The common stock was sold at $2.10 per share, an approximate 15% discount to the market price ($2.46) of APPY at deal announcement. Aegis Capital Corporation acted as the exclusive agent on the transaction and the investors were not disclosed. Placement Agent counsel was Reed Smith, and issuer counsel was Ballard Spahr. The transaction is expected to close by Nov.
Robotic arm maker MAKO Surgical Corp. (MAKO) has raised $40 million in a CMPO/Overnight transaction. The common stock was sold at $13.15 per share, an approximate 0% discount to the market price ($13.21) of MAKO at deal announcement. Piper Jaffray & Co. acted as the exclusive agent on the transaction, and Moelis & Company acted as financial advisor. Placement Agent counsel was Latham & Watkins, and issuer counsel was Foley & Lardner.
Neurological treatment developer XenoPort (XNPT) announced that it has raised $40 million in a Common Stock transaction at two prices with investor Glaxo Group Ltd. Some $20 million of the common stock was sold at $10.86 per share, an approximate 44% premium to the market price ($7.53) of XNPT at deal announcement. The other $20 million was sold at $9.13 per share, an approximate 21% premium. The Placement Agent was not disclosed. The transaction closed on Nov. 9, 2012.
BioTime (BTX) announced that it has secured up to $25 million in an ATM (At the Market) transaction with Cantor Fitzgerald & Co. The purchase price is the prevailing market price at the time of the Draw Down Notice. Placement Agent counsel was Reed Smith, and issuer counsel was Thompson, Welch, Soroko & Gilbert. See the PlacementTracker Deal Summary.
